Stay updated with breaking news from Replimune Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
During the forecast period 2023 to 2033, the oncolytic adenovirus market is expected to grow at a value of 7.5% CAGR, according to Future Market Insights. By the year 2033, the global market for oncolytic adenovirus is expected to rise up to a market valuation of US$ 250 Billion. Growth of the market can be attribut...
Replimune Group, Inc. (NASDAQ:REPL – Get Rating) has been given an average recommendation of “Buy” by the seven research firms that are currently covering the firm, MarketBeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokers that have updated their coverage on the stock […]
Replimune Group, Inc. (NASDAQ:REPL – Get Rating) has been given an average recommendation of “Buy” by the seven research firms that are currently covering the firm, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokers that have updated their coverage on the stock […]
Shares of Replimune Group, Inc. (NASDAQ:REPL – Get Rating) have been assigned an average recommendation of “Buy” from the seven ratings firms that are covering the stock, MarketBeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12-month target price among brokers that have issued a report on the […]
Replimune Group, Inc. (NASDAQ:REPL – Get Rating) fell 3.8% during trading on Wednesday . The company traded as low as $19.24 and last traded at $19.24. 16,801 shares changed hands during trading, a decline of 97% from the average session volume of 567,215 shares. The stock had previously closed at $20.00. Analyst Upgrades and Downgrades […]